

# APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035



06<sup>th</sup> November 2025

The Secretary,  
Bombay Stock Exchange Ltd (BSE)  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Scrip Code - 508869**  
**ISIN INE437A01024**

The Secretary,  
National Stock Exchange,  
Exchange Plaza, 5th Floor  
Plot No.C/1, 'G' Block  
Bandra - Kurla Complex  
Bandra (E)  
Mumbai - 400 051.  
**Scrip Code-**  
**APOLLOHOSP**  
**ISIN INE437A01024**

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for three and six months ended September 30, 2025.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website [www.apollohospitals.com](http://www.apollohospitals.com).

Kindly note of the same.

Thanking You,

Yours faithfully,  
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN  
Sr. VICE PRESIDENT - FINANCE  
AND COMPANY SECRETARY



SANKARAN  
ARAYANA  
N MUTHU  
KRISHNAN

Digitally signed  
by  
SANKARANARAY  
ANAN MUTHU  
KRISHNAN  
Date: 2025.11.06  
18:41:44 +05'30'

IS/ISO 9001 : 2000


**Regd. Office :**  
19, Bishop Gardens,  
Raja Annamalaipuram,  
Chennai - 600 028.

**General Office :**  
"Ali Towers" III Floor,  
#55, Greams Road,  
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681  
Telefax : 044 - 2829 0956  
Email : [investor.relations@apollohospitals.com](mailto:investor.relations@apollohospitals.com)  
Website : [www.apollohospitals.com](http://www.apollohospitals.com)



# **Apollo Hospitals Enterprise Limited**



**Earnings Update Q2 FY26**

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the “Company”) to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “intends” or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.


This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

 <b>Financial Performance Snapshot &amp; Business Segment wise Update</b>	<b>4-9</b>
 <b>Consolidated Financials</b>	<b>11-12</b>
 <b>Healthcare Services</b>	<b>14-23</b>
 <b>Diagnostics &amp; Retail Health (AHLL)</b>	<b>25-28</b>
 <b>Digital Health &amp; Pharmacy Distribution (Apollo HealthCo)</b>	<b>30-35</b>
 <b>Annexure</b>	<b>37-38</b>




# Financial Performance Snapshot Q2FY26



		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT	Growth YoY(%)
<b>Healthcare Services</b>		31,690	↑ 9%	7,810	24.6%	↑ 8%	4,101	12.9% ↑ 13%
Apollo HealthCo	Offline PD ^	23,347	↑ 16%	1,812	7.8%	↑ 19%		
	Online PD^ & 24 7	3,259	↑ 22%	(710)	Vs (1,006) in Q2FY25			
	<b>Total HealthCo</b>	26,606	↑ 17%	1,102	4.1%		731	2.7% ↑ 284%
<b>AHLL</b>		4,739	↑ 17%	500	10.6%	↑ 21%	(60)	
<b>Consolidated</b>		63,035	↑ 13%	9,412	14.9%	↑ 15%	4,772	7.6% ↑ 26%

^PD:- Pharmacy Distribution




# Financial Performance Snapshot H1FY26



		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT	Growth YoY(%)
<b>Healthcare Services</b>		61,042	↑ 10%	14,988	24.6%	↑ 12%	7,940	13.0% ↑ 15%
Apollo HealthCo	Offline PD ^	44,981	↑ 17%	3,481	7.7%	↑ 19%		
	Online PD^ & 24 7	6,343	↑ 24%	(1,442) Vs (2,169) in H1FY25				
	<b>Total HealthCo</b>	51,324	↑ 18%	2,040	4.0%		1,300	2.5%
<b>AHLL</b>		9,090	↑ 18%	903	9.9%	↑ 25%	(141)	
<b>Consolidated</b>		121,456	↑ 14%	17,931	14.8%	↑ 20%	9,100	7.5% ↑ 33%

^PD:- Pharmacy Distribution

# Largest Pan India Hospital Chain




	Hospitals	Capacity Census Beds <sup>1</sup>	Operational Census Beds
<b>Overall Total</b>	73	10,200	9,483
<b>Owned Hospitals</b>	45	8,767	8,050
<b>Managed Hospitals</b>	6	790	790
<b>Day Surgery &amp; Cradle (AHLL)</b>	22	643	643

<sup>1</sup>Capacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc.

### Healthcare Services Q2 FY26 Snapshot

- 162,928 In-patients** ↑ 2%
- ₹ 173,318 Avg Revenue per IP Patient** ↑ 9%
- 69% Occupancy**

- Revenue** → ₹ 31,690 Mio ↑ 9%
- EBITDA** → ₹ 7,810 Mio ↑ 8%
- Margin** → **24.6%**



# AHLL: Retail Health

Apollo Health & Lifestyle Ltd



## Out-of-Hospital care

- Outpatient Clinics
- Diagnostics
- Day Surgery centers
- Single Specialty Facilities :- Dialysis, Sugar and Dental

## Organizing the unorganized

- Pathology – Organized chains represent only ~30%
- Mother and Child, Specialized Surgical Centers
- IVF Centers

## AHLL Q2 FY26 Snapshot

  
2,422  
Diagnostics  
Centers

  
300 Clinics

  
161  
Dialysis Centers

  
254  
Dental Centers

Revenue ₹ 4,739 Mio ↑ 17%

EBITDA ₹ 500 Mio ↑ 21%

Margin 10.6%


Significant **opportunity to grow** the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer



Apollo HealthCo Ltd

## Offline Pharmacy Distribution

- India's largest **Organized Pharmacy Platform** with presence in ~1,200+ cities/ towns spread across 22 States and 5 union territories.
- **6,928 Operating Stores** as on 30<sup>th</sup> Sep 2025.
- **Serving ~ 9.1 lacs customers** 24 x 7 everyday.
- **Private and Generic Label sales at 16.5% (offline) for Q2 FY26.**



## Apollo 24/7

### Unmatched Size

- **44 Mn.+** Registered Users – **9.5 Lacs** Daily Active Users
- Serving consumers through **network of 6,928 pharmacies**

### Industry-leading Growth at scale

- Platform GMV: INR 723 Cr. in Q2FY26, growth of 16% over Q2 FY25

### Full stack digital healthcare platform

- First-in-class AI enabled technologies including India's first Clinical Intelligence Engine

## Apollo Telehealth\*

- Provides **comprehensive remote healthcare services.**
- Offers **specialized telehealth solutions** like **24/7 Tele-Emergency** and **Tele-Consultancy.**
- Expands access to **healthcare in distant regions**, improving quality of life.
- Operates and maintains **Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries,** and is also engaged in organizing **Screening Camps** and development of **Diagnostic Centres** for setting up healthcare awareness programs

\*Division of AHEL

## Health Co Q2 FY26 Snapshot



6,928 Outlets



~15.25% Omni Private label / Generic sales

Revenue

₹ 26,606 Mio ↑ 17%

EBITDA

₹ 2,361 Mio ↑ 26%  
(excl 24/7 operating cost & ESOP)

Margin

8.9%



Virtual Doctor Consultation



Online Booking : Hospitals & Diagnostics



Online Medicine delivery



Health Insurance



Patient e-health records



Condition management



## Hospitals


- Apollo Hospitals accomplished the completing over 51 lakh surgeries; 27,000 solid organ transplants in the 42 years of service to the Nation.
- Apollo Children's Hospitals, Chennai, completed over 6,000 pediatric cardiac surgeries and 10,000 interventional procedures since its inception.
- Apollo Hospitals, Jubilee Hills, Hyderabad performed Deep Brain Stimulation on a 4-year-old with severe cervical dystonia - among the youngest globally to undergo this procedure.
- Apollo Proton Cancer Centre (APCC), Chennai, performed India's first robotic telesurgery for resectable colorectal cancer — conducted remotely across 2,200 km between APCC Chennai and SS Innovations in Gurgaon.

## AHLL

- Introduced pain relief and repair therapies including PEMF Ion Therapy, Infrared, Stem Cell, Exosome Therapy etc in Bengaluru Clinic
- Expansion of test-menu to include Penta Marker Screening to detect advanced fetal chromosomal abnormalities, Y-Chromosome Microdeletion Analysis to detect spermatogenic failure, Anti-GAD65 Antibody Detection by Indirect Immunofluorescence (IIF), Facioscapulohumeral Muscular Dystrophy (FSHD) to detect repeat contractions, Extended HPV Genotyping (FDA Approved), Heavy & Trace Metal Profile by ICPMS, Whole Genome by Long Read Sequencing, C1-Esterase Inhibitor for diagnosis of hereditary angioedema, Von Willebrand factor Ag to assess for VWD, Factor VIII-IX-XI-XII assay for bleeding disorders and Pre-implantation Genetic Screening to enhance IVF outcomes
- PLAC Test (detects Heart Blockage) Campaign launched on World Heart Day across all Channels to build awareness
- Apollo Dialysis launched nationwide Nutrition Week campaign combining clinician education, patient activations and coordinated brand promotions

## Apollo HealthCo

- Improved Pharma Order Unit Economics through reduced order splits, higher AOV, lower discounts & HC burn and increased convenience fees.
- New User Acquisition driven by an omni-channel strategy, with marketing spend significantly lower than last year and similar to the previous quarter.
- Boosted Diagnostic GMV by expanding into 18 new cities and introducing new channels such as pharmacy stores.
- Deeper Penetration in hospitals through JMC offerings and focus on multi specialities coverage
- Expanded the Insurance business across brands, products, cities, along with network growth driven by recruitment and tech enablement.



# Consolidated Financials

# Consolidated Financials Q2FY26

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
Q2FY26	Total Revenues	31,690	4,739	26,606	63,035
	EBITDA (Pre 24 7 Cost)	7,810	500	2,361	10,670
	margin (%)	24.6%	10.6%	8.9%	16.9%
	24/7 Operating Cost			-935	-935
	ESOP(Non Cash expense)			-324	-324
	<b>EBITDA</b>	<b>7,810</b>	<b>500</b>	<b>1,102</b>	<b>9,412</b>
	<b>margin (%)</b>	<b>24.6%</b>	<b>10.6%</b>	<b>4.1%</b>	<b>14.9%</b>
	EBIT	6,238	136	860	7,233
	margin (%)	19.7%	2.9%	3.2%	11.5%
	PBT	6,082	-69	735	6,747
	margin (%)	19.2%	-	2.8%	10.7%
<b>PAT (Reported)</b>	<b>4,101</b>	<b>-60</b>	<b>731</b>	<b>4,772</b>	
Q2FY25	Total Revenues	29,032	4,039	22,822	55,893
	EBITDA (Pre 24 7 Cost)	7,220	414	1,874	9,508
	margin (%)	24.9%	10.3%	8.2%	17.0%
	24/7 Operating Cost			-1,197	-1,197
	ESOP(Non Cash expense)			-156	-156
	<b>EBITDA</b>	<b>7,220</b>	<b>414</b>	<b>521</b>	<b>8,155</b>
	<b>margin (%)</b>	<b>24.9%</b>	<b>10.3%</b>	<b>2.3%</b>	<b>14.6%</b>
	EBIT	5,804	117	389	6,310
	margin (%)	20.0%	2.9%	1.7%	11.3%
	PBT	5,424	-41	190	5,574
	margin (%)	18.7%	-	0.8%	10.0%
<b>PAT (Reported)</b>	<b>3,643</b>	<b>-46</b>	<b>190</b>	<b>3,788</b>	
<b>YOY Growth</b>					
Revenue		9%	17%	17%	13%
EBITDA		8%	21%	112%	15%
PAT		13%	-	284%	26%

- ✓ Overall Consolidated Revenue grew by 13% to ₹ 63,035mio.
- ✓ EBITDA grew by 15% to ₹ 9,412 mio.
- ✓ Consolidated PAT grew by 26% to ₹ 4,772 mio.

# Consolidated Financials H1FY26


₹ Mio	Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol	
<b>H1FY26</b>	Total Revenues	61,042	9,090	51,324	121,456
	EBITDA (Pre 24   7 Cost)	14,988	903	4,506	20,397
	margin (%)	24.6%	9.9%	8.8%	16.8%
	24/7 Operating Cost			-1,898	-1,898
	ESOP(Non Cash expense)			-569	-569
	<b>EBITDA</b>	<b>14,988</b>	<b>903</b>	<b>2,040</b>	<b>17,931</b>
	<b>margin (%)</b>	<b>24.6%</b>	<b>9.9%</b>	<b>4.0%</b>	<b>14.8%</b>
	EBIT	11,847	207	1,551	13,606
	margin (%)	19.4%	2.3%	3.0%	11.2%
	PBT	11,427	-158	1,306	12,574
	margin (%)	18.7%	-	2.5%	10.4%
	<b>PAT (Reported)</b>	<b>7,940</b>	<b>-141</b>	<b>1,300</b>	<b>9,100</b>
	<b>H1FY25</b>	Total Revenues	55,405	7,700	43,643
EBITDA (Pre 24   7 Cost)		13,437	723	3,595	17,755
margin (%)		24.3%	9.4%	8.2%	16.6%
24/7 Operating Cost				-2,497	-2,497
ESOP(Non Cash expense)				-352	-352
<b>EBITDA</b>		<b>13,437</b>	<b>723</b>	<b>746</b>	<b>14,906</b>
<b>margin (%)</b>		<b>24.3%</b>	<b>9.4%</b>	<b>1.7%</b>	<b>14.0%</b>
EBIT		10,682	144	461	11,287
margin (%)		19.3%	1.9%	1.1%	10.6%
PBT		9,990	-177	61	9,874
margin (%)		18.0%	-	0.1%	9.2%
<b>PAT (Reported)</b>		<b>6,927</b>	<b>-147</b>	<b>61</b>	<b>6,840</b>
<b>YOY Growth</b>					
Revenue	10%	18%	18%	14%	
EBITDA	12%	25%	-	20%	
PAT	15%	-	2034%	33%	

- ✓ Overall Consolidated Revenue grew by 14% to ₹ 121,456 mio.
- ✓ EBITDA grew by 20% to ₹ 17,931 mio.
- ✓ Consolidated PAT grew by 33% to ₹ 9,100 mio.

	HCS	Health Co	AHLL
<b>Gross Debt</b>	21,660	4,254	2,986
<b>Cash &amp; Cash Equivalents*</b>	30,143	924	1,160
<b>Net Debt</b>	-8,483	3,330	1,827

\*Includes investments in Liquid funds and FDs of ₹ 27,345 mio.

<b>Consol Gross Debt</b>	28,901
<b>Consol Net Debt</b>	-3,326



# Healthcare Services

## Hospitals



₹ Mio	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
No of Hospitals	45	45		45	45	
Operating beds	8,050	7,994	1%	8,050	7,994	1%
Occupancy	69%	73%		67%	70%	
IP Discharges	162,928	159,968	2%	314,486	306,830	2%
ALOS	3.14	3.35	-6%	3.14	3.34	-6%
<b>Avg revenue per In Patient (₹)</b>	<b>173,318</b>	<b>159,379</b>	<b>9%</b>	<b>172,819</b>	<b>158,839</b>	<b>9%</b>
<b>Revenue</b>	<b>31,690</b>	<b>29,032</b>	<b>9%</b>	<b>61,042</b>	<b>55,405</b>	<b>10%</b>
<b>EBITDA (Post Ind AS 116)</b>	<b>7,810</b>	<b>7,220</b>	<b>8%</b>	<b>14,988</b>	<b>13,437</b>	<b>12%</b>
<b>margin (%)</b>	<b>24.6%</b>	<b>24.9%</b>	<b>-22 bps</b>	<b>24.6%</b>	<b>24.3%</b>	<b>30 bps</b>
<b>EBIT</b>	<b>6,238</b>	<b>5,804</b>	<b>7%</b>	<b>11,847</b>	<b>10,682</b>	<b>11%</b>
<b>margin (%)</b>	<b>19.7%</b>	<b>20.0%</b>	<b>-31 bps</b>	<b>19.4%</b>	<b>19.3%</b>	<b>13 bps</b>
<b>PBT</b>	<b>6,082</b>	<b>5,424</b>	<b>12%</b>	<b>11,427</b>	<b>9,990</b>	<b>14%</b>
<b>PAT</b>	<b>4,101</b>	<b>3,643</b>	<b>13%</b>	<b>7,940</b>	<b>6,927</b>	<b>15%</b>
<b>Margin</b>	<b>12.9%</b>	<b>12.5%</b>	<b>39 bps</b>	<b>13.0%</b>	<b>12.5%</b>	<b>51 bps</b>


- ✓ Healthcare Services Revenue grew by 9% in Q2FY26 (Inpatient Volume grew by 2% ; Price of and case mix of 7%)
- ✓ Q2FY25 had a higher incidence of seasonal medical admissions, leading to a high base, whereas medical admissions were low in Q2FY26. This low growth in medical admissions was partly offset by 14% increase in Revenue from CONGO Specialties.
- ✓ The reduction in Bangladesh patients has had an impact of 1% on HCS Revenue in Q2FY26.
- ✓ Average Revenue per In patient grew by 9% to ₹173,318 in Q2FY26

**Capital employed**  
(ROCE – H1FY26)



**₹ 78,295**

**ROCE 30.3%**


\* capital employed excludes CWIP of ₹ 10,412 mio toward new projects under development



# Inpatients Revenue Mix H1FY26



\* Oncology includes Radiotherapy and Chemotherapy



# Healthcare Services: Expansion Plan




To add 4,400 capacity beds ~3,600 census beds over the next 5 years

Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)
<b>Expected commissioning : FY26 -FY27</b>				
Royal Mudhol, Pune	Hospital Asset Acquisition	384	305	₹ 665
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220	₹ 310
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹ 550
Gurgaon, NCR	Hospital Asset Acquisition	480	400	₹ 1,210
Defence Colony, Delhi	Greenfield - Asset Light	42	27	₹ 65
Sarjapur-1	Acquisition - Leased facility	180	150	₹ 290
Jubilee Hills (Expansion)	Brownfield	100	80	₹ 230
Secunderabad (Expansion)	Brownfield	100	80	₹ 70
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 170
<b>Expected commissioning : FY26 -FY27</b>		<b>2,071</b>	<b>1,687</b>	<b>₹ 3,560</b>
<b>Expected commissioning :FY29-FY30</b>				
Worli, Mumbai	Greenfield	575	500	₹ 1,315
Sarjapur-2	Greenfield	500	400	₹ 944
OMR, Chennai	Greenfield	600	500	₹ 945
Varanasi, U.P	Greenfield	400	300	₹ 640
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110	₹ 570
<b>Expected commissioning : FY29-FY30</b>		<b>2,415</b>	<b>1,970</b>	<b>₹ 4,734</b>
<b>Grand Total</b>		<b>4,486</b>	<b>3,657</b>	<b>8,294</b>

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros

**Total Project Cost of ~₹ 8,300crs with Balance to be spent of ~₹5,800crs.**



# Healthcare Services : Operational Snapshot




- Metros:** Chennai, Hyderabad, Bangalore, Mumbai, Kolkata and Delhi
- Non Metros (includes Tier1 & Tier2 cities)** Ahmedabad, Bhubaneshwar, Lucknow, Indore, Guwahati, Madurai, Trichy, Nellore, Vizag, Kakinada, Mysore, Nashik, Bilaspur, Rourkela, Karimnagar, Karur and Karaikudi.

H1FY26	6 Metros	Non Metros
<b>Operating Beds</b>	4,630	3,420
<b>Occupancy</b>	70%	63%
<b>ARPP -IP<sup>^</sup></b>	205,257	124,364
<b>ROCE</b>	31%	27%

<sup>^</sup>Avg revenue per In Patient

	Pan India					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
<b>Operating Beds</b>	8,050	7,994	0.7%	8,050	7,994	0.7%
<b>Bed Occupancy Rate (%)</b>	69%	73%		67%	70%	
<b>Inpatient volume</b>	162,928	159,968	1.9%	314,486	306,830	2.5%
<b>Outpatient volume<sup>(1)</sup></b>	618,743	588,923	5.1%	1,185,871	1,110,921	6.7%
<b>Inpatient ALOS (days)</b>	3.14	3.35	-6.3%	3.14	3.34	-6.2%
<b>Total Net Revenue (₹ mio)<sup>(2)</sup></b>	34,811	31,721	9.7%	67,055	60,715	10.4%
<b>Avg revenue per In Patient</b>	173,318	159,379	8.7%	172,819	158,839	8.8%

<sup>1</sup> Outpatient Volume represents New Registrations only | <sup>2</sup> Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control



# Tamil Nadu Region



Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore



	Tamil Nadu Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	2,066	2,048	0.9%	2,066	2,048	0.9%
Bed Occupancy Rate (%)	63%	64%		62%	64%	
Inpatient volume	39,356	39,280	0.2%	76,878	76,799	0.1%
Outpatient volume <sup>(1)</sup>	173,797	155,022	12.1%	334,497	305,077	9.6%
Inpatient ALOS (days)	3.05	3.07	-0.6%	3.06	3.12	-2.2%
Total Net Revenue (₹ mio)	10,411	9,558	8.9%	20,235	18,574	8.9%
Avg revenue per In Patient	205,263	184,447	11.3%	203,926	183,473	11.1%

## H1FY26

### Chennai

Operating Beds

1,401

Occupancy

63%

ARPP-IP ^

226,742

### Others

Operating Beds

665

Occupancy

59%

ARPP-IP ^

144,780

### Current Beds

Chennai

1,401

Total

2,066

### Post Expansion

1,901

2,566

+500

## Expansion Plan

Location	Nature	Total Beds	Census Beds
OMR, Chennai	Greenfield	600	500

<sup>1</sup> Outpatient Volume represents New Registrations only. ^ Avg revenue per In Patient

# AP, Telangana Region

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada



	AP, Telangana Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	1,290	1,240	4.0%	1,290	1,240	4.0%
Bed Occupancy Rate (%)	68%	74%		65%	69%	
Inpatient volume	25,592	24,078	6.3%	48,863	43,807	11.5%
Outpatient volume <sup>(1)</sup>	76,013	82,414	-7.8%	151,401	150,101	0.9%
Inpatient ALOS (days)	3.14	3.53	-10.9%	3.16	3.56	-11.3%
Total Net Revenue (₹ mio)	5,567	4,862	14.5%	10,581	8,929	18.5%
Avg revenue per In Patient	185,203	170,270	8.8%	183,924	170,251	8.0%

## H1FY26

### Hyderabad

Operating Beds

787

Occupancy

71%

ARPP-IP ^

193,878

### Others

Operating Beds

503

Occupancy

57%

ARPP-IP ^

160,579

Hyderabad

Current Beds

787

Post Expansion

1,357

Total

1,290

+570

1,860

## Expansion Plan

Location	Nature	Total Beds	Census Beds
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300
Jubilee Hills (Expansion)	Brownfield	100	80
Secunderabad (Expansion)	Brownfield	100	80
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110
<b>Total</b>		<b>715</b>	<b>570</b>

<sup>1</sup> Outpatient Volume represents New Registrations only. ^ Avg revenue per In Patient



	Karnataka Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	781	772	1.2%	781	772	1.2%
Bed Occupancy Rate (%)	70%	80%		69%	77%	
Inpatient volume	17,765	18,935	-6.2%	34,718	36,230	-4.2%
Outpatient volume <sup>(1)</sup>	80,336	72,052	11.5%	150,872	132,263	14.1%
Inpatient ALOS (days)	2.83	3.01	-5.9%	2.85	3.00	-5.0%
Total Net Revenue (₹ mio)	3,721	3,442	8.1%	7,264	6,561	10.7%
Avg revenue per In Patient	175,034	153,333	14.2%	175,709	153,080	14.8%

	Current Beds	Post Expansion
Bangalore	568	1,243
Total	781	1,456

+675

### Expansion Plan

Location	Nature	Total Beds	Census Beds
Malleswaram & Mysore Expansion	Brownfield	140	125
Sarjapur-1	Acquisition - Leased facility	180	150
Sarjapur-2	Greenfield	500	400
<b>Total</b>		<b>820</b>	<b>675</b>

### H1FY26

#### Bangalore

Operating Beds

568

Occupancy

69%

ARPP-IP ^

190,737

#### Others

Operating Beds

213

Occupancy


70%

ARPP-IP ^

129,900

<sup>1</sup> Outpatient Volume represents New Registrations only

^ Avg revenue per In Patient



	Eastern Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	1,818	1,847	-1.6%	1,818	1,847	-1.6%
Bed Occupancy Rate (%)	79%	80%		75%	78%	
Inpatient volume	36,361	35,442	2.6%	69,678	68,376	1.9%
Outpatient volume <sup>(1)</sup>	118,237	126,025	-6.2%	228,539	236,186	-3.2%
Inpatient ALOS (days)	3.62	3.86	-6.3%	3.59	3.83	-6.5%
Total Net Revenue (₹ mio)	6,763	6,273	7.8%	12,872	11,982	7.4%
Avg revenue per In Patient	148,337	139,652	6.2%	146,833	138,464	6.0%

## H1FY26

### Kolkata

Operating Beds

736

Occupancy

79%

ARPP-IP ^

219,490

### Others

Operating Beds

1,082

Occupancy

73%

ARPP-IP ^

101,659

### Current Beds

Kolkata

736

### Post Expansion

956

Total

1,818

2,038

## Expansion Plan

Location	Nature	Total Beds	Census Beds
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220

<sup>1</sup> Outpatient Volume represents New Registrations only. ^ Avg revenue per In Patient ; Kolkata ARPP-IP Grossed up for fee-for-service doctor fees.



	Western Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	888	870	2.1%	888	870	2.1%
Bed Occupancy Rate (%)	60%	67%		56%	61%	
Inpatient volume	14,939	14,543	2.7%	28,072	27,086	3.6%
Outpatient volume <sup>(1)</sup>	58,359	60,504	-3.5%	109,198	112,038	-2.5%
Inpatient ALOS (days)	3.29	3.70	-11.1%	3.26	3.57	-8.8%
Total Net Revenue (₹ mio)	2,759	2,449	12.7%	5,223	4,615	13.2%
Avg revenue per In Patient	155,325	139,821	11.1%	156,027	139,655	11.7%



## Expansion Plan

Location	Nature	Total Beds	Census Beds
Royal Mudhol, Pune	Hospital Asset Acquisition	384	305
Worli, Mumbai	Greenfield	575	500
<b>Total</b>		<b>959</b>	<b>805</b>

## H1FY26

### Mumbai

Operating Beds

392

Occupancy

69%

ARPP-IP ^

182,974

### Others

Operating Beds

496

Occupancy

46%


ARPP-IP ^

125,514

<sup>1</sup> Outpatient Volume represents New Registrations only. ^ Avg revenue per In Patient



	Northern Region					
	Q2FY26	Q2FY25	YoY	H1FY26	H1FY25	YoY
Operating Beds	1,207	1,217	-0.8%	1,207	1,217	-0.8%
Bed Occupancy Rate (%)	72%	74%		71%	73%	
Inpatient volume	28,915	27,690	4.4%	56,277	54,532	3.2%
Outpatient volume <sup>(1)</sup>	112,001	92,906	20.6%	211,364	175,256	20.6%
Inpatient ALOS (days)	2.76	2.98	-7.4%	2.79	2.97	-6.2%
Total Net Revenue (₹ mio)	5,590	5,137	8.8%	10,880	10,054	8.2%
Avg revenue per In Patient	162,510	157,742	3.0%	163,200	156,534	4.3%



## H1FY26

### Delhi NCR

Operating Beds

746

Occupancy

74%

ARPP-IP ^

191,207

### Others

Operating Beds

461

Occupancy

66%


ARPP-IP ^

122,038

## Expansion Plan

Location	Nature	Total Beds	Census Beds
Gurgaon, NCR	Hospital Asset Acquisition	480	400
Varanasi, U.P	Greenfield	400	300
Lucknow (Expansion), U.P	Brownfield	200	160
Defence Colony, Delhi	Greenfield - Asset	42	27
<b>Total</b>		<b>1122</b>	<b>887</b>

<sup>1</sup> Outpatient Volume represents New Registrations only. ^ Avg revenue per In Patient



# Diagnositics & Retail Health

## Apollo Health & Lifestyle Ltd

## Primary Care



- ▶ Core revenues of Primary Care grew by ~16% YoY in H1 FY26, as a result of strengthening of corporate & partner outreach
- ▶ Preventive Health-checks volume grew by ~42% YoY in H1 FY26
- ▶ Implemented pain relief & repair therapy programs in Bengaluru Clinic
- ▶ 3 New Clinics & 15 New Dialysis Centres added in H1 FY26

## Diagnostics



- ▶ Net addition of 10 Satellite Labs & 203 Collection Centers to the network
- ▶ Wellness segment volume grew by ~31% YoY in H1 FY26 which contributed to ~15% of Diagnostics revenue
- ▶ Test-menu expansion to cover Facioscapulohumeral Muscular Dystrophy, Extended HPV Genotyping, Pre-implantation Genetic Screening, Heavy and Trace Metal Profile by ICPMS, Von Willebrand factor Ag, C1-Esterase Inhibitor
- ▶ Focus on operational excellence & productivity improvement via automation etc. in H2

## Specialty Care




- ▶ Sector witnessing strong competitive headwinds
- ▶ Spectra: Revenue growth in H1 FY26 primarily driven by renovated Centres of Jaipur & Delhi
- ▶ Cradle: ~7% YoY revenue growth in H1 FY26.
- ▶ Fertility: ~6% YoY revenue growth in H1 FY26. Also established a new fertility Knowledge Centre

		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
<b>Q2FY26</b>	Revenue	1,242	1,827	1,884	-214	4,739
	EBITDA	206	220	208	-133	500
	<b>margin (%)</b>	<b>16.5%</b>	<b>12.0%</b>	<b>11.0%</b>		<b>10.6%</b>
	EBIT	135	146	-7	-139	136
	PAT	103	130	-167	-153	-88
<b>Q2FY25</b>	Revenue	1,093	1,345	1,808	-208	4,039
	EBITDA	203	181	209	-178	414
	<b>margin (%)</b>	<b>18.5%</b>	<b>13.4%</b>	<b>11.6%</b>	-	<b>10.3%</b>
	EBIT	130	141	20	-173	117
	PAT	83	132	66	-347	-66
<b>Growth</b>						
	Revenue	14%	36%	4%	-	17%
	EBITDA	1%	22%	-1%	-	21%

- ✓ AHLL revenue & EBITDA grew by 17% & 21% YoY in Q2 FY26 respectively; primarily driven by growth in Diagnostics
- ✓ Primary care revenue grew by 14% YoY in Q2 FY26 due to enhanced corporate & partner outreach
- ✓ Specialty care revenue grew by 4% YoY in Q2 FY26 due to intensified sector competition

	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra <sup>1</sup>	Birthing Centers <sup>1*</sup>	Total
<b>Network</b>	300	79	254	161	2,422	23	34	3,273
<b>Footfalls / Day</b>	2,803	560	237	2,660	24,535	90	113	30,999
<b>Gross ARPP</b>	2,395	3,356	6,686	1,630	733 <sup>#</sup>	103,259	85,513	1,578



		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
<b>H1FY26</b>	Revenue	2,377	3,352	3,767	-405	9,090
	EBITDA	403	339	448	-286	903
	<b>margin (%)</b>	<b>16.9%</b>	<b>10.1%</b>	<b>11.9%</b>	-	<b>9.9%</b>
	EBIT	260	198	43	-295	207
	PAT	192	174	-260	-311	-204
<b>H1FY25</b>	Revenue	2,058	2,509	3,533	-400	7,700
	EBITDA	382	291	393	-343	723
	<b>margin (%)</b>	<b>18.6%</b>	<b>11.6%</b>	<b>11.1%</b>	-	<b>9.4%</b>
	EBIT	239	214	32	-341	144
	PAT	162	199	-55	-521	-214
<b>Growth</b>						
	Revenue	16%	34%	7%	-	18%
	EBITDA	5%	17%	14%	-	25%


- ✓ AHLL revenue & EBITDA grew by 18% & 25% YoY in H1 FY26 respectively; primarily driven by growth in Diagnostics
- ✓ Primary care revenue and EBITDA grew by 16% and 5% YoY in H1 FY26 respectively due to enhanced corporate & partner outreach
- ✓ Specialty care revenue and EBITDA grew by 7% and 14% YoY in H1 FY26 respectively

	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra <sup>1</sup>	Birthing Centers <sup>1*</sup>	Total
<b>Network</b>	300	79	254	161	2,422	23	34	3,273
<b>Footfalls / Day</b>	2,662	541	239	2,591	22,678	90	104	28,903
<b>Gross ARPP</b>	2,405	3,298	6,639	1,636	725 <sup>#</sup>	106,188	84,409	1,618


# Diagnostics : Key Parameters



Gross Revenue (INR Mn)



EBITDA (INR Mn)<sup>1</sup>



Operational footprint (as of Sep 30, 2025)


~340+ Cities presence

111 Labs


2,300+ Collection Centres

3,700+ Pick-up Points (PUPs)

Avg. Footfalls per day & Avg. gross realization per patient (INR)\*




Network Growth – Collection Centers<sup>#</sup>



# Rationalized the commission structure for collection centers, resulting in reduction of centers in Q2 FY25 & Q4FY25

1. EBITDA post IND AS 116;

\* Footfalls and ARPV for diagnostics represent outpatient / external business



# Digital Health & Pharmacy Distribution **Apollo HealthCo**

# India's Largest Omni-Channel Healthcare Platform



## Apollo 247 Digital Platform

~44 Mn+ Registrations


~13,250+ Doctors

Daily Active Users 9.5 Lakh

Daily Consultations 16,000+

Daily Medicine Orders ~56,000

Daily Sample Collections ~3,000+




## Apollo Pharmacy Platform

6,928 Stores

Added – Q2 186

~15.2%

Omni Private label / generics mix - Q2 FY26



- Virtual Doctor Consultation
- Online Booking : Hospitals & Diagnostics
- Online Medicine delivery
- Insurance
- Patient e-health records
- Condition management

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
Q2FY26	Total Revenues	23,347	3,259	26,606
	EBITDA (Pre 24 7 Cost)#	1,812	548	2,361
	margin (%)	7.8%	16.8%	8.9%
	24/7 Operating Cost		-935	-935
	ESOP(Non Cash expense)		-324	-324
	<b>EBITDA</b>	<b>1,812</b>	<b>-710</b>	<b>1,102</b>
	<b>margin (%)</b>	<b>7.8%</b>	<b>-</b>	<b>4.1%</b>
	EBIT			860
	PBT			735
	PAT (Reported)			734
Q2FY25	Total Revenues	20,144	2,678	22,822
	EBITDA (Pre 24 7 Cost)#	1,527	346	1,874
	margin (%)	7.6%	12.9%	8.2%
	24/7 Operating Cost		-1,197	-1,197
	ESOP(Non Cash expense)		-156	-156
	<b>EBITDA</b>	<b>1,527</b>	<b>-1,006</b>	<b>521</b>
	<b>margin (%)</b>	<b>7.6%</b>	<b>-</b>	<b>2.3%</b>
	EBIT			389
	PBT			190
	PAT (Reported)			190
Revenue		16%	22%	17%
EBITDA (Pre 24 7 Cost)		19%	58%	26%

# Excluding 24|7 operating Cost and ESOP Non-Cash Charge



## Healthco (Q2' FY26 vs Q2' FY25)

- 17% growth in revenue in Q2' FY26 vs Q2' FY25.
- **4x PAT** in Q2'FY26 (Rs. 734 Mn) vs Q2'FY25 (Rs. 190 Mn)
- Lowest cash loss of Rs 386 Mn in Q2'FY26



## Omnichannel Healthcare Division:

- Omnichannel Pharmacy (AHL+ APL) : Revenue of Rs 34,292 Mn in Q2' FY26 compared to Rs. 28,768 Mn in Q2' FY25 (growth of 19%).
- Serving ~1 Mn transactions every day





## Digital Operational Metrics :

- Platform GMV : Rs 7,230 Mn in Q2' FY26, growth of 16% over Q2' FY25 (6,212 Mn)
- Consistent source for new customer acquisition (launch of 19 mins & Omni Acquisition).
- Continuous Improvement in quantitative parameters in Q2' FY26 vs Q2' FY25:
  - 30% YoY growth in Online Pharma Transactions
  - 30% YoY growth in Transacting users



## Offline Segment

- 12% YoY growth in offline transactions (8.7 cr Vs 7.8 cr year back).



\*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
<b>H1FY26</b>	Total Revenues	44,981	6,343	51,324
	EBITDA (Pre 24 7 Cost)#	3,481	1,024	4,506
	margin (%)	7.7%	16.1%	8.8%
	24/7 Operating Cost		-1,898	-1,898
	ESOP(Non Cash expense)		-569	-569
	<b>EBITDA</b>	<b>3,481</b>	<b>-1,442</b>	<b>2,040</b>
	<b>margin (%)</b>	<b>7.7%</b>	<b>-</b>	<b>4.0%</b>
	EBIT			1,551
	PBT			1,306
	<b>PAT (Reported)</b>			<b>1,304</b>
<b>H1FY25</b>	Total Revenues	38,513	5,130	43,643
	EBITDA (Pre 24 7 Cost)#	2,915	680	3,595
	margin (%)	7.6%	13.3%	8.2%
	24/7 Operating Cost		-2,497	-2,497
	ESOP(Non Cash expense)		-352	-352
	<b>EBITDA</b>	<b>2,915</b>	<b>-2,169</b>	<b>746</b>
	<b>margin (%)</b>	<b>7.6%</b>	<b>-</b>	<b>1.7%</b>
	EBIT			461
	PBT			61
	<b>PAT (Reported)</b>			<b>61</b>
Revenue	17%	24%	18%	
EBITDA (Pre 24 7 Cost)	19%	51%	25%	

# Excluding 24|7 operating Cost and ESOP Non-Cash Charge

## Healthco (H1' FY26 vs H1' FY25)

- 18% growth in revenue in H1' FY26 vs H1' FY25.
- **H1'FY26 PAT of Rs. 1,304 Mn vs Rs. 61 Mn in H1' FY25**

## Omnichannel Healthcare Division:


- Omnichannel Pharmacy (AHL+ APL) : Revenue of Rs 65,933 Mn in H1' FY26 compared to Rs. 54,916 Mn in H1' FY25 (growth of 20%).
- Apollo Telehealth (under AHEL) – Generated Revenue of Rs 326 Mn, with a positive EBITDA of Rs 6 mn in H1 FY26.
- Serving ~1 Mn transactions every day

## Digital Operational Metrics :


- Platform GMV : Rs 14,050 Mn in H1' FY26, growth of 20% over H1' FY25 (11,745 Mn)
- Consistent source for new customer acquisition (launch of 19 mins & Omni Acquisition). New Lob- Insurance started gaining attraction
- Continuous Improvement in quantitative parameters in Q2' FY26 vs Q2' FY25:
  - 36% YoY growth in Online Pharma Transactions
  - 33% YoY growth in Transacting users

## Offline Segment

- 13% YoY growth in offline transactions (16.7 cr Vs 14.8 cr year back).



\*Cash loss/profit is EBITDA post Ind As excluding ESOP expense



- Proposes to undertake below transactions sequentially, via a scheme of arrangement, subject to requisite corporate and regulatory approvals

## Step 1

- Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform (shares of AHEL in Apollo Healthco Ltd) & remote telehealth division of AHEL into New Co

## Step 2

- Amalgamation of Apollo Healthco Ltd with and into New Co

## Step 2


- Amalgamation of Keimed Private Limited with and into New Co

**Upon effectiveness of the Scheme (Post Shareholder and NCLT approval),  
New Co to become an 'Indian Owned and Controlled Company' (IOCC), and apply for listing on stock exchanges**

# Composite scheme: Shareholding Structure




## Shareholder approved Resultant Group Structure in August 2024




## Resultant Group Structure Proposed Now (Post all approvals)

- Automatic listing of New Co
- Direct participation of AHEL shareholders in New Co



\*\* Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger/ demerger process is ~ 2.5%.

Estimated Listing by Q4FY27 post all approvals.




# Combined Financials Metrics | Snapshot H1FY26

(₹ mio)




	FY24	FY25	Offline Pharma Distribution	+	Online Pharma Distribution+247	=	Total Healthco	+	Keimed	=	Combined Q2	Combined H1'FY26
Revenue	137,701	163,772	23,347		3,259		26,606		38,304		47,883	92,179
EBITDA, Pre INDAS	9,614	11,180	1,753		543		2,296		1,025		3,321	6,499
EBITDA %	7.0%	6.8%	7.5%		16.7%		8.6%		2.7%		6.9%	7.1%
24/7 Operating cost	-6,186	-4,781	-		-935		-935		-		-935	-1,898
ESOP Non Cash charge	-891	-1,076	-		-324		-324		-		-324	-569
EBITDA, Pre IndAS	2,533	5,322	1,753		-716		1,037		1,025		2,062	4,033
EBITDA %	1.8%	3.2%	7.5%		N.M.		3.9%		2.7%		4.3%	4.4%
Excluding Digital	6.7%	6.4%									6.2%	6.2%

Company expects to achieve INR 250 bn of run rate annualized revenue in Q4 FY27 with 7% EBITDA



# Annexure




# Basis of Consolidation



AHEL Standalone Hospitals (100% Ownership)	Location
Chennai Main	Chennai
ACI - Chennai	Chennai
Tondiarpet - Chennai	Chennai
FirstMed - Chennai	Chennai
Apollo Children's Hospital	Chennai
Apollo Specialty, Vanagaram	Chennai
ASH Perungudi	Chennai
Women & Child, Shafee Mohammed Road	Chennai
Apollo Proton & Cancer care	Chennai
Madurai	Madurai
Karur	Karur
Karaikudi	Karaikudi
Trichy	Trichy
Nellore	Nellore
Hyderabad	Hyderabad
Bilaspur	Bilaspur
Rourkela	Odisha
Mysore	Mysore
Vizag (old & new)	Vizag
Karim Nagar	Karim Nagar
Bhubaneswar	Bhubaneswar
Jayanagar	Bangalore
Nashik	Nashik
Malleswaram	Bangalore
Navi Mumbai	Mumbai

Subsidiaries	Location	Description	AHEL Ownership
<b>Material Subs</b>			
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services Platform	99.68%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	68.84%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	70.99%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
<b>Other Subs</b>			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Apollo Gleneagles PET-CT Pvt Ltd (w.e.f 30 <sup>th</sup> Sep 2025)	Hyderabad	Diagnostics	100.00%
Apollo HealthTech	India	Digital Omni-Channel Healthcare services Platform	100.00%
<b>Associates</b>			
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapeutics Pvt Ltd	India	Stemcell Banking	37.75%



# IND AS - 116 : Impact on P&L and Balance Sheet –H1FY26



## AHEL Standalone (post IND AS 116)



### Balance sheet

Right of use Asset as of 30 <sup>th</sup> Sep, 2025	↑	13,350
Lease liabilities as of 30 <sup>th</sup> Sep, 2025	↑	13,381
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓	2,109



### Profit & Loss

Revenue		
Other expenses (Lease rent)	↓	577
EBITDA	↑	577
Amortisation	↑	363
EBIT	↑	214
Finance charge	↑	350
PBT	↓	136

## AHEL Consolidated (post IND AS 116)



### Balance sheet

Right of use Asset as of 30 <sup>th</sup> Sep, 2025	↑	24,873
Lease liabilities as of 30 <sup>th</sup> Sep, 2025	↑	26,461
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax)	↓	3,052



### Profit & Loss

Revenue		
Other expenses (Lease rent)	↓	1,338
EBITDA	↑	1,338
Amortisation	↑	895
EBIT	↑	444
Finance charge	↑	783
PBT	↓	339

**Thank you**